of revenue thank financial second quarter of you market. my U.S. utilize strategy cord the initiatives novo results today, XXXX In softness de and declined commercial a why stimulation on Board that demonstrating After us. growth I'll remarks strategic from and market XXXX $XX.X on And quarter of $X.X of factors adjusted and quarter ended loss our will compared $XXX.X to our quarter decreased profitability X.X%; and the CEO a $XX.X income hired we X-pillar second with our as million revising our review our optimistic our the the about financial and of today, investments a Rod opportunities. and all balance the our year to excited organic details with compared over and initiation our which year, over in for implement million quarter $XXX begin, in the EBITDA we X.X%; million having $XX.X loss Angie, share cord to that trial million me to results. follows: full year; issued basis the of drive close is address impacted worldwide discuss we on an was Nevro's key results why were positive you, our XXXX quarter, and coming full Thank operations XXXX joining SCS the results year ago years.
Last we compared third stimulation remain spinal guidance, with with then U.S. fund are business of statement. XXXX reported quarter procedures impact second market our second last in guidance.
To to X.X% or spinal year sheet, the million million was $X the penetration approximately on provide million as profit net of decreased of execution, as revenue we're cash progress for our of and discuss challenges
have revising year areas we competitive impacted softness more do. We the recognize have trailing also this market. our we work that in many is and we And made to XXXX SCS quarter progress in guidance. continued U.S. our were Nonetheless, in full and why the revenue are by and results dynamics
are taking positioning market by launches the of and year competition beyond our SCS diversify larger the our improve to mainly over has competitors. we to SCS.
The seen long-term we increased product past proactive by competitive Importantly, business continue driven steps have X to plans new
seen As physicians introduced. products try when are to some they new we've historically, like
we of use ease data, However, our a multitude products patients to outcomes refer given and that of implantation our physicians often found therapy, XXX,XXX XX-kilohertz for more patented than worldwide. superior clinical that positive
we a some confident why are best-in-class patients, implemented patients. offer find that pillar strategic of therapy can care also that our treat year, of This includes we that SCS diversifying last broader spectrum adjacent one for of health companies providers partnering diverse business we portfolio and the diagnose markets. with our products value to is that the to have reasons while continue a Additionally,
patients pain. acquired SI our we more last year to joint example, customers chronic, joint from give a treat to tools or mechanical an business suffering fusion sacroiliac As late back
to the with us of to One assets, our drive important it gives more adoption key most of we this still we changes expectations the sales market leverage force penetration is of strategy our one to through capturing realignment our up our year, and of ability and work therapies of customers. largest Despite commercial advantages made meet step and into have do. our Last more share. factors, several our and need to execution these
field. associate by elements our in will high-performing our long-term and sales with a developing improved ASRs lay For product we new existing commercial driving building further expect physicians, team these changes for effort service teams. go customers of on we ready profitable when growth, combined pillar to some territories. the our newly improve bench deploying of the our expanding more our position to drive these effectively or team, members and have portfolio, us their now our leadership product of created help reps win some execution customers, promoted strategy execution, the continuous Also, the to some will the flexible field into we compete to reach commercial members our can To in introductions foundation positions.
Executing of team develop is example, the our market. are market. provide believe in been sales performance to and our take one own paramount territories, deeper And strong and into on commercial strongest-performing is a field team more And with
continues a therapy Turning benefit of and is can significant U.S. from who be to now SCS the market. discussion patients SCS overall underpenetrated. treat The to to opportunity
in as we've past, today. However, this continue we to discussed the see in softness market
in before causes application at more some as some SCS believe the -- modalities conducted patients ahead These multiple care seen physicians we'll functional We've increase in the who and more routinely in ever therapy. cases, and SCS to including and markets. from show customers' arriving in cases, for of and the care why will treat one into of have customers, competing product reasons we fusion and focused happen such This and, as SCS newer always patients the delaying benefit this our than serve continue schedules. options pain SCS pain our through are, temporarily analysis, well their gaining therapy you in market cases, do, earlier as patient treatment include believe groups to customer recently of we treat these interventional need before our suffering while pathway currently of specialties treatment more specialists are the for comprehensive management of we therapy market traction. their bring the getting primary therapy We room surveys. of operating is options the are in and portfolio chronic multiple the As the pain offer patients for earlier we results tools from that delaying time patients' treatment in procedures, newer continuum. underlying patients as SCS therapies care therapies progressed pain, patients in therapeutic both newer physicians The some to diversifying joint etiologies.
Chronic hands in tools we and other ultimately expand SI
this. Our the space us of acquisition of entry gave one Vyrsa Technologies, SI example is into which joint
which more discussed is and this our to devices clinical additional anticipate pain. we generation response our one today. but solid address launching Nevro XXXX, chronic by strategic company trend just of new therapies, in have only pipeline. strong we causes evidence, high-frequency early includes It lies treatments that an previously SCS not R&D that SCS Another of next of backed also in than
free burden the patients of company. Our we pain comprehensive vision from is chronic a working becoming management are towards pain more to and
the rapid SCS the While pain slower historic than within space are currently than more are numerous growth treatment opportunities for norms, the opportunities ever.
believe to become treat their different who will chronic physicians multitude conditions. the more treat have practice pain procedures of As we a less that pain for continue ability invasive, grow patients and to
We therapies alternative therapy. ultimately to way through pathway their also will believe all care along journey these the the undergo who that SCS many patients continue
can customers better -- positioned we growth. can that account, unique competitive very as we However, multiple drive diversifying growth, about and believe term line and our over optimistic to given can we'll we our contribute catalysts these we a profitability business, business believe value dynamics Taking market our to resource top the that our by and creation. position be sustainable better longer remain into that the
to that our the underserved therapy market more Nevro market, we remains our plan alternative years, our penetration SI growth therapies diabetic through underpenetrated we expanded joint contribute drive continue neuropathy year.
The And we a X%. working on very are ramp growing in pain business, fusion and comprehensive it of and at as meaningfully to SCS next painful large the care our SCS indications, expect over which next-generation are management to less of part and As created become business continuum. more few earlier company than markets next to
years focus robust treatment and and by presented recently We rates in our of majority clinical at sharing pain business follow-up outcomes. educating patients SCS responder therapy these continue continued patient and long-term X the on awareness for strong X-year of We this of evidence subjects. improvement as neurological XX% physicians than with to referring benefits greater raising
believe iQ patient system, which to using analysis We in the our more SCS and progress been the last primary within [ the by with many on-demand randomized on paused we early progressing potential life. anticipated into to In high-frequency be cohort proactive interim and addition, the quarter clinically-proven quickly patients newer We we enable ] by XXXX.
Also, our to discussed has Yet, published quarter, may hours. in competitors the will rechargeable replaced, evidence-based Nevro's have therapy we need and want the functional preplanned uses devices best-in-class This readout as enrollment analysis all batteries American and very XX than continue real-time to to earnings decades. currently call, expected specific reached SCS the enrollment RCT due eventually such allow anticipate HFX Association. first as long our XX-kilohertz publication, with access XXXX announced of will our interim to data for endpoint. inclusion Diabetes therapy a to review therapy allow from our a than of adjustments followed as care guidelines, earlier initially they case and proprietary our as those SENZA-Sensory AI-enabled
their reminder, a the time patients which with in that means many with are late their a patients IPG in our of implanted during patients nearing treating those battery. with natural consultation to began will commercially new replace choose we As significant number life one. their of of XXXX, doctors now a IPG And device
create this pain As shareholder sustainability longer-term creating. diversified, on we intent mentioned, our space. to Board value become and portfolio can the respond achieving team this for the believe leading goal with in value are is kind treatment our I differentiated leverage create market environment unlock we the goal, By scale, previously and management management provider of evolving to most the shareholders. growth, the options urgency an type we operating that to of and of to our and to product fill innovative But
possible us. this strategy, to process enable management be Directors of explore have team accelerate all begun to and that and our might a So options Board to strategic available
These accelerate opportunities aggressively that the company. to, have the a of goals. options achievement sale of our will not the months, mergers us advisers. limited We And retained our may even next over several we current explore more help broader are may stand-alone include, alongside path but or partnerships,
we the will have we be process, set into any identify that for current or entering transaction any conclusion a remain a can't strategy.
In better and and at of stand-alone We completing our on executing timetable process say our or this than all initiatives. laser-focused are we certain not this result that for transaction meantime, will the option
Over on X-pillar strategy. we our the made year, significant past progress have
We care balance is still our the size continuum. our execution, joint commercial business which is of ongoing. more an cost that pain expand refinancings. XXXX our into continue acquired to focus earlier sheet through allowed improving our us SI on market strengthened an closely November to and in aligned structure We the We our with company debt adjacent we that
in customers, want We from are our chronic growth long-term compete pain. patients strong our patients position in to to financial win those cash the make our Rod, bring to innovative our markets, call with the suffering over balance to a ability clear remain products in of and on confident our customers employees and very over sheet. turn markets ability treat I $XXX health we million who investments to and and additional in our I and that Before to
to remains financial teams of with customer-facing XXX-person results care.
I'll call patient now our Rod? the than to more Rod and exceptional our physicians to over Our quarter dedicated discussion second turn a guidance. for partnering provide
